Tesamorelin
Tesamorelin
Quantity
Minimum order is: 3 boxsShipping
Supplier will ship within 3–10 days of confirmed payment.
Goods will be dispatched from United Kingdom, China port.
Shipping is offered under FOB terms — the supplier covers costs to the named port of shipment.
Payment: T/T (Wire Transfer)
Sample available · $250.00/sample
Euromart Suppliers order protection
Every payment you make is secured with strict SSL encryption and PCI DSS data protection protocols
Make free local returns for defects on qualifying purchases
Claim a refund if your order doesn't ship, is missing, or arrives with product issues
Meet your supplier
Distributor / Wholesaler • 3 yr • 
UNITED KINGDOM
56%
On-time delivery rate
≤24h
Response Time
75
Employee Size
$500K
Annual Revenue
588
Products Sold
Location
Belfast, United Kingdom
KEY FEATURES
Therapeutic Class: Synthetic growth hormone–releasing factor (GRF) analog
Primary Indication: Reduction of excess abdominal fat in adults with HIV‑associated lipodystrophy
Mechanism of Action: Stimulates pituitary growth hormone release → increases IGF‑1 → reduces visceral adipose tissue
Clinical Benefit: Proven reduction in abdominal fat without affecting limb or subcutaneous fat distribution
Brand Names: Egrifta®, Egrifta SV®
TECHNICAL SPECIFICATIONS
Molecular Type: Synthetic peptide (44‑amino acid analog of human GRF)
Formulation: Sterile lyophilized powder for reconstitution
Dosage strength
Egrifta®: 1 mg and 2 mg vials
Egrifta SV®: 2 mg vials (small‑volume, more concentrated)
Administration: Daily subcutaneous injection into abdominal area
Preparation: Reconstituted with supplied sterile diluent before injection
Storage: Refrigerated at 2–8 °C; do not freeze; use reconstituted solution immediately
Regulatory Identifiers: Each vial carries an NDC code (U.S.) or equivalent international code for compliance
AVAILABLE CONFIGURATIONS
Format and Delivery:
Lyophilized powder vials (single‑use)
Supplied with diluent for reconstitution
Concerntration and Dosage:
Standard Egrifta® vials (1 mg, 2 mg)
Egrifta SV® vials (2 mg, reduced diluent volume)
Packaging and Labeling:
Cartons containing vials + diluent
Professional labeling with regulatory compliance identifiers
US
GB
